Alan Ho is an Oncology physician. ClinicalTrials.gov lists 20 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
212-744-2191Registry record last updated 1 Feb 2016.
Clinical trials
- A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
- Day One BiopharmaceuticalsProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers
Sloan-Kettering Inst Can Research
FY2026$216,447R01FD008181 - Improving efficacy of radioiodine treatment of thyroid cancer
Sloan-Kettering Inst Can Research
FY2025$471,416R01CA249663 - Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers
Sloan-Kettering Inst Can Research
FY2025$194,528R01FD008181
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”